【摘要】：隨著程序性凋亡因子1受體(programmed death-1,PD-1)及其配體(PD-L1)抑制劑單藥治療在晚期非小細胞肺癌(non-small cell lung cancer,NSCLC)的二線和一線治療中相繼取得突破性進展,晚期NSCLC的診治策略正在逐漸發(fā)生演變和優(yōu)化。免疫聯(lián)合治療擴大受益人群、提高療效,目前已經(jīng)在一線治療領域取得初步結(jié)果,有多項III期隨機對照研究正在進行中。本文將對免疫檢查點抑制劑在晚期NSCLC一線治療中的現(xiàn)狀和前景進行綜述。
[Abstract]:With the development of single drug therapy of programmed apoptosis factor 1 receptor (programmed death-1,PD-1) and its ligand (PD-L1) inhibitor in the treatment of advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC), there has been a breakthrough in the second and first line treatment of apoptosis factor 1 receptor (programmed death-1,PD-1) and its ligand (PD-L1) inhibitor. The strategy of diagnosis and treatment of advanced NSCLC is gradually evolving and optimizing. Immunization combined therapy has expanded the benefit population and improved curative effect. At present, preliminary results have been obtained in the field of first-line treatment, and many randomized controlled studies of III stage are under way. This article reviews the current status and prospects of immunocheckpoint inhibitors in the first-line treatment of advanced NSCLC.
【作者單位】： 浙江省腫瘤醫(yī)院;
【分類號】：R734.2
，

本文編號：2368140